Methods for treating myocardial infarction comprising adminis... by Alain Lacampagne

The major cause of acute CM, the precursor to heart failure, is myocardial ischemia (see section Mitochondrial Dysfunction in IHD), whereas less acute forms of CM are idiopathic, inherited, or caused by chronic diseases, such as hypertension and diabetes mellitus. This review summarizes efforts to date in targeting mitochondria for IHD and CM therapy and outlines emerging drug targets in this field. Notably, there are a number of overlapping therapies for both these diseases, and as such novel therapeutic options for one condition may find use in the other. As such, the mitochondrion is a potential untapped target for new IHD and CM therapies. 2, 3 However, despite promising mitochondria-targeted drugs emerging from the laboratory, very few have successfully completed clinical trials. Mitochondrial dysfunction plays a key role in the pathogenesis of IR injury and cardiomyopathy (CM).

1 Although interventions, such as thrombolysis and percutaneous coronary intervention (PCI), have proven efficacious in ischemia and reperfusion (IR) injury, the underlying pathological process of IHD, laboratory studies suggest further protection is possible, and an expansive research effort is aimed at bringing new therapeutic options to the clinic. Ischemic heart disease (IHD) is a significant cause of morbidity and mortality in Western society. This review summarizes efforts to date in targeting mitochondria for ischemic heart disease and cardiomyopathy therapy and outlines emerging drug targets in this field. As such, the mitochondrion is a potential untapped target for new ischemic heart disease and cardiomyopathy therapies. However, despite promising mitochondria-targeted drugs emerging from the laboratory, very few have successfully completed clinical trials. Mitochondrial dysfunction plays a key role in the pathogenesis of ischemia and reperfusion injury and cardiomyopathy. Although interventions, such as thrombolysis and percutaneous coronary intervention, have proven efficacious in ischemia and reperfusion injury, the underlying pathological process of ischemic heart disease, laboratory studies suggest further protection is possible, and an expansive research effort is aimed at bringing new therapeutic options to the clinic. Ischemic heart disease is a significant cause of morbidity and mortality in Western society.

Customer Service and Ordering Information.

Stroke: Vascular and Interventional Neurology.

Journal of the American Heart Association (JAHA).Circ: Cardiovascular Quality & Outcomes.Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB).

Methods for treating myocardial infarction comprising adminis... by Alain Lacampagne